Qiagen (NYSE:QGEN) Rating Increased to Hold at UBS Group

UBS Group upgraded shares of Qiagen (NYSE:QGEN) to a hold rating in a report released on Wednesday,Zacks reports.

Several other analysts have also recently issued reports on QGEN. Morgan Stanley reiterated an “overweight” rating on shares of Qiagen in a research note on Friday. Barclays set a $40.00 price objective on Qiagen and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Kepler Capital Markets set a $38.60 price objective on Qiagen and gave the company a “hold” rating in a research note on Thursday, June 25th. Weiss Ratings raised Qiagen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, August 17th. Finally, Stifel Nicolaus set a $40.00 price objective on shares of Qiagen in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $43.51.

Qiagen Trading Up 0.6%

Shares of QGEN stock opened at $42.39 on Wednesday. The stock has a market capitalization of $8.74 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 4.20 and a beta of 0.63. The company’s fifty day simple moving average is $42.20 and its two-hundred day simple moving average is $40.18. Qiagen has a 1 year low of $32.53 and a 1 year high of $57.81. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.02. The company had revenue of $535.04 million during the quarter, compared to analysts’ expectations of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, analysts anticipate that Qiagen will post 2.43 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its stake in shares of Qiagen by 12.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock valued at $379,072,000 after purchasing an additional 906,589 shares in the last quarter. Deutsche Bank AG lifted its stake in Qiagen by 9.7% in the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after purchasing an additional 697,342 shares during the last quarter. Amundi lifted its stake in Qiagen by 12.4% in the first quarter. Amundi now owns 4,757,681 shares of the company’s stock worth $190,498,000 after purchasing an additional 524,959 shares during the last quarter. Boston Partners purchased a new stake in Qiagen during the third quarter valued at about $179,450,000. Finally, Norges Bank bought a new position in shares of Qiagen during the fourth quarter valued at about $166,500,000. 70.00% of the stock is currently owned by institutional investors.

Qiagen Company Profile

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.